The so-azlled entactogens 3,4-methylenedioxymethamphetamine ([MDMAJ also known as "Ecstasy," or "Adam"j and its analog 3,4-methylenedioxyethamphetamine ([MDEJ also known as "Eve") exert similar psychotropic effects in humans. Two do uble-blind placebo-controlled psychometric studies with normal control subjects were conducted. Placebo or MDE (140 mg) was administered orally to eight male volunteers at 1:30 P.M. and to six subjects (3 male, 3 female) at 11 P.M. Psychologic tests and clinical ratings were performed 1 hour before the administration of the drugs, as well as 2, 5, and 24 hours after drug intake and 7 days thereafter in the first study. In the second study, measures were taken at times -1, + 8. 5, + 24 hours, and + 7 days. The majority of the KEY WORDS: Entactogens; MDE; MDMA; Psychologic effects According to anecdotal evidence, 3,4-methylenedioxy methamphetamine ([MDMA] also known as "Ecstasy," "Adam," and "XTC") and 3,4-methylenedioxyethamphe tamine ([MDE] also known as "Eve") exert unique psy chologic effect in humans, discriminating them from chemically related substances like the stimulant am phetamine and the hallucinogens 3,4-methylenedioxy amphetamine (MDA) and 3,4,5-trimethoxy-phene-
psychotropic effects resembled those that have already been described in anecdotal reports. The substance produced a partially controllable state of enhanced insight, empathy, and peaceful feelings. All subjects displayed a general stimulation with increased psychomotor drive, logorrhea, and facilitation of communication. One of the fourteen volunteers developed a toxic psychosis. One volunteer displayed a dysphoric reaction, one suffered from episodes of anxiety for some days after the experiment. The findings support the hypothesis that MDMA and MDE represent a novel pharmacologic class. lNeuropsychopharmacology 8: [171] [172] [173] [174] [175] [176] 1993] thylamine ([mescaline] Shulgin 1986; Nichols 1986) . Although MDMA was assigned to a Schedule I status by the Drug Enforcement Agency in 1985, there is an ongoing discussion about its potential uses in psy chotherapy and the possible adverse neurotoxic effects it may have (Beck 1990; Peroutka 1990; Battaglia et al. 1988; Ricaurte et al. 1988; Gibb et al. 1990; Schmidt et al. 1987) . After the scheduling of MDMA, its N-ethyl analog, MDE, served as an substitute for recreational users (Beck 1990) .
Like MDMA and MDA the N-ethylated MDE has a high affinity at reuptake sites of central catecholamin ergic, dopaminergic, and serotonergic neurons and is taken up via a fluoxetine-sensitive carrier mechanism. These substances cause reuptake inhibition and release of the mentioned transmitters (Johnson et al. 1988) .
Neurotoxicity studies of MDMA and MDE found a depletion of serotonin and long-term axon damage after the acute or chronic administration of these agents in a wide dose range (Stone et a1. 1987; Battaglia et al. 1988; Ricaurte et al. 1987) . Studies found MDE to be less neurotoxic than MDMA (Schmidt et a1. 1987) .
Various nonsystematic observations suggest that entactogens are different from hallucinogenic drugs. There are no reports of individuals or drug-addicts who take frequent or large amounts of MDMA or MDE for extended periods of time. The reason for this is that the "positive" effects of the drug seem to diminish and the "negative" effects seem to increase with time (Greer et al. 1986 ). Data on the psychologic effects of MDMA and MDE are limited. Although there are some reports of panic reactions and "bizarre and risky behavior" (Dowl ing et a1. 1986) during peak intoxication from the drug, MDMA and MDE enjoy a reputation for producing a well-controllable emotionally peaceful experience with enhanced insight, empathy, and closeness to others with only rare occasions of severe toxicity. More chronic psychologic problems such as delayed anxiety disorders have been observed in a few individuals following an MDMA experience (Seymour 1986 ). These fIndings un derscore a potential danger of recreational use or "self therapy" by individuals who run the risk of exacerbat ing emotional problems.
It was hypothesized, that MDMA and MDE might constitute a novel pharmacologic class called "entacto gens." Nichols (1986) gives the following defInition of this new term, " . . . it seemed that the Latin root of this word, "tactus, " would be appropriate as part of the term. Addition of the Greek roots en (within or inside) and gen (to produce) created the term entactogen, hav ing the connotation of producing a touching within." From a therapeutic viewpoint, it should be noted that antidepressant and anxiolytic properties have been reported (Greer et a1. 1986 ).
To our knowledge, this is the fIrst report of a con trolled investigation of the psychologic effects of MDE . Data from two separate studies, one study on neuroen docrine and cardiovascular effects, and a second study on the effects of MDE on sleep electroencephalography (EEG) were evaluated. The EEG study was done in or der to specify the effects of MDE on sleep patterns that are known to be closely connected with certain neu rotransmitters. The leading idea of the study was that a distinct sleep pattern distinguishing MDE from am phetamine and hallucinogens might be detectable. The neuroendocrine, cardiovascular, and sleep-EEG data are reported elsewhere (Gouzoulis et a1. 1992a,b, in press ).
MATERIALS AND METHODS

Subjects and Study Design
Study 1. In a randomized double-blind placebo-con trolled cross-over study, eight physically and mentally NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 healthy male volunteers ranging in age from 29 to 50 years (mean 38 years) were included. Subjects were selected 3 to 7 days before the experiment by screening with the structured clinical interview for DSM-III-R (German version, Wittchen et a1. 1987 ) to ensure that they had no personal or family history of psychiatric disorders in fIrst degree relatives. In addition, the Freiburger Personality Inventory (FPI), the Vegetative Lability Scale (BL), and the State-Trait Anxiety Scale (STAI)-X2 were performed at this time. To exclude physical disorders, subjects were screened by means of physical examination, EEG, and electrocardiography. All subjects were academics (seven physicians and one engineer), were fully informed of the toxicology study results at the time of their participation, and gave writ ten informed consent.
Study 2. In a similar design, six healthy volunteers (3 male, 3 female) ranging in age from 28 to 33 years (mean 29.5 years) participated. All participants were academics (fIve physicians and one psychologist). In the female subjects, pregnancy was ruled out by an ap propriate test.
All 14 subjects had been without any medication for at least 3 months prior to the study, and had not been subject to excessive alcohol or caffeine intake, stressful life events, shift work, or time shifts greater than 3 hours during the preceding 3 months. None of the subjects met the DSM-III-R criteria for alcohol or substance abuse. None of the subjects had previous ex periences with MDE. Two subjects each reported one single experience with MDMA, two subjects had one or two previous experiences with hallucinogens some years ago. The studies were approved by the local ethics committee at the University of Freiburg, Germany.
Substances
The MDE used in this study was synthesized at the In stitute of Pharmaceutics, University of Tiibingen, and was obtained in the form of 70 mg capsules. Placebo capsules were obtained from the same institute. Each subject received 140 mg MDE (2 to 3 mg/kg of body weight), a dose commonly taken for recreational and therapeutical use (Seymour 1986; Beck 1990 ). It should be noted that quantitative data on the pharmacokinetic aspects of MDE are not yet available. In particular, noth ing is known about its bioavailability after oral inges tion under fasted and nonfasted conditions in humans. From the pattern of metabolites that have been detected in the urine, the existence of two metabolic pathways (O-desmethylization and N-desalkylization) in human beings can be inferred. All metabolites are excreted as sulphate and/or glucuronide in the urine (K-A Kovar, unpublished data).
Psychometric Measurements
All subjects were rated by two experienced psychiatrists with the Manic-State Rating Scale ([MSRS] Beigel et al. 1971) . To evaluate the general psychologic effects of the drug, the following self-rating scales were used: the FPI revised (Fahrenberg et al. 1984) ; the STAI-Xl (Laux et aI.1981) ; the Depression Scale ([OS] von Zerssen 1986); the Vegetative Lability Scale (BL) (von Zerssen 1986); the Adjective Mood Scale, "Befmdlichkeitsskala" ([BFS] von Zerssen 1986); a questionnaire for the assessment of "Altered States of Consciousness" (APZ), with its dimensions oceanic boundlessness (OSE); dread for ego-dissolution (AlA); and visionary restructuralization (VUS) (Dittrich 1985) .
For the evaluation of cognitive functions, the fol lowing tests and measures were used: the Benton Test (Instruction A, Benton 1971); repetition of numbers for ward and backwards (Hamburg-Wechsler Intelligence Evaluation [HAWIE] subtest 3, 1964); and counting backwards (100 minus 7, in a series, until reaching 51). In addition to these measures, two semistructured in terviews (self-reports) were obtained 1 day and 1 week after the experimental session.
Experimental Procedure Study 1. Subjects arrived at the hospital at 12:00 A.M. and received a standardized calorie-and electrolyte balanced diet for lunch. Beginning at 1:00 P.M., subjects had to rest supine on a bed in a single room while they were observed by a video camera with a monitor lo cated in the adjacent observation unit. They were aff orded the opportunity to communicate with inves tigators by intercom. Either MOE or placebo wa � given orally with some liquid at 1:30 P.M. PsychometrIC tests were performed before the ingestion of MDE or placebo, as well as 2, 5, and 24 hours after ingestion of the drug, and again 7 days later. Study 2. Subjects spent a total of 4 nights in � he sl . eep laboratory, 1 adaptation night and 1 consecutIve mght while taking MOE (140 mg orally) or placebo. Two to 6 weeks later, subjects spent another adaptation night and another consecutive night taking either placebo or MDE (crossover). During the 2 weeks preceding the sleep EEG examination, each subject was instru � ted to go to bed between 10:30 : .M. and 11:30 P.M . . ThiS was done in order for the subjects to become acchmated to the "lights off" time. Drugs were administered at 11 . :00 P.M., just before lights were switched off. ObservatIon of the subject was possible by infrared video camera, and communication was made possible by intercom. Psychometric tests were performed before drug intake (at 10:00 P.M.), after awakening (at 7:30 A.M.), as well as 24 hours and 7 days after drug intake.
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RESULTS
Study 1
Trait measures: under baseline conditions, results of the FPI-R were in the normal range, except for the dimension of "openness," in which a higher than av erage mean score was obtained. The ST AI-X2 yielded normal results. State measures: in the MSRS, a signiftcant difference between MOE and placebo was found at time 1 (2 hours after MOE intake, p = 0.005, Student's t-test two-tailed, see ng. 1).
In the STAI-Xl, no signiftcant difference between MDE and placebo was found. The analysis of individual state anxiety scores, however, showed a decrease of anxiety in seven of the eight subjects. One subject (num ber 8), however, displayed a marked increase of anxi ety under the influence of MOE. In the semi-structured interview, this subject described this state as follows, "The onset of the effect is rapid. Within seconds, clouds appeared within my head, and afterwa � ds the � e was a marked lack of concentration. It was ImpOSSIble to read. Bits and pieces of thought pass by but cannot be put together. This state of restlessness and lack of coor dination was experienced as markedly unpleasant and senseless. The accompanying somatic phenomena were also experienced as unpleasant: restlessness, palpita tions, hyperventilation, tickling paresthesia in the nngers, dry mouth, tension in the muscles around the mouth." As can be seen from this self-report, somatic symptoms accompanying generalized anxiety were markedly present. No signiftcant correlation between state and trait anxiety, as measured by ST AI-X2 and STAI-Xl was found. No signiftcant diff erence between MOE and placebo was found on the OS, BFS, or BL All subjects fell asleep about 30 minutes after "lights off, " awoke after they had slept for 30 to 60 minutes, and stayed awake for at least 150 minutes. Three of the subjects reported experiences of depersonalization, such as a "light feeling in the body, " a "sense of not laying in bed but rather floating in the air," a feeling "as if the clock has come to a standstill," and an ex perience "as if the eyes were sticking out of the head." Two subjects noted "mystic" experiences. One subject developed a psychotic state about 1 hour after the in take of MOE, which lasted for about 2% hours. In this state, he suffered from vivid auditory and visual hallu cinations, delusions of reference, and loss of control of thought. His psychotic symptoms were completely abated without the use of any medication when assisted by a clinician who "talked him down" (for a detailed report, see Gouzoulis et al. 1992c) . One subject suffered from depressive affect of 30 minutes duration in the 5 days following the experiment. No difference between MOE and placebo was found in any of the ratings (BL, BFS, STAI-Xl, or OS).
Studies 1 and 2
Data from the APZ questionnaire of the two studies were pooled (n = 14). As can be seen from Table I , MOE produced highly signifIcant differences compared to placebo in all three scales.
The semi-structured interviews revealed that the drug intake influenced the subjects' attitudes for at least 7 days. Some subjects felt "enlightened" by the ex perience, and reported an increased interest in ques tions regarding their attitudes towards life, self, general aims, and interpersonal relationships.
DISCUSSION
Standard psychometric methodology and a double blind placebo-controlled cross-over study design was used to obtain data on the psychologic effects of MOE, an agent that has been suggested to represent a new class of psychoactive substances labeled entactogens, in 14 normal subjects. The major effects of MOE were a reduction of anxiety, an increased drive with pro nounced partly euphoric and partly depressed mood, and an improved responsiveness in, and openness to, communication. Psychotic symptoms were present in only one subject, who suffered from a schizophrenia- like psychotic episode for 21f2 hours. Three subjects ex perienced episodes of depersonalization and dereali zation, and two subjects reported "mystical" experi ences. For several days, one of these tv.u subjects developed a depressive state, including episodes of anxiety.
Although most anecdotal reports state that MDMA and MOE are "safe" drugs, dysphoric reactions, pani c attacks (Whitaker et al. 1989; Seymour 1986) , and ''bi zarre and risky behavior" (Dowling et al. 1987) were reported in single cases of entactogen-users. However, these reports are diffIcult to interpret, as the effects might have been caused by interactions with other in gested substances, such as alcohol. Furthermore, the precise chemical qualities of the substances used were unknown because of their illegal production. Our data suggest that these anecdotal reports represent valid ob servations of the effects of the substance, i.e., that en tactogens may exert psychotomimetic effects. More over, the frequency of such serious toxic reactions ma y have been underestimated by those authors who made estimates by merely relying upon assumptions about the frequency of use and the frequency of respective reports.
It is noteworthy that the more severe psychologic reactions occurred in the second experiment in which the subjects took the substance at bedtime and woke up spontaneously (from deep sleep) about one hour later. As it is generally known that the effects of psychoac tive drugs are highly dependent on the setting in which they are taken, it is likely that the severity of the substance-induced changes can be attributed to the spe cial setting adopted in the second study.
As it is generally known that the effects of psychoac tive substances are dependent upon the set, i.e., per sonal factors (including educational level), and as all subjects were professional people from a medical envi ronment, we are not able to comment on the generality of our fIndings with respect to subjects from different socioeconomic and educational backgrounds.
The hitherto anecdotally reported powerful an tidepressant and anxiolytic properties of MOE seem to be different from the effects of standard antidepressant and anxiolytic agents. According to our data, MDE pro duced a decrease in anxiety and a increase of euphoric and depressed mood with an augmented drive being present at the same time. This seemingly paradoxical finding of both emotional states, manic-like temper and depressed mood, may be regarded as the result of a general increase in responsiveness to emotions. Under the influence of MOE, these states were experienced in a calm and relaxed manner, almost without any ac companying anxiety. Moreover, the fact that MOE does not lea d to a marked reduction of general sensitivity and cognitive functioning, may add to the emotional responsiveness of the subjects. Unlike hallucinogenic drugs, MOE did not disturb perception, formal thought processes, or memory, nor did it produce psychotic symptoms such as hallucina tions, with the exception of one case. Although all the scales of the APZ questionnaire revealed signiflcant drug effects, these effects were mainly concerned with the dissolution of ego-boundaries, experiences of derealization, and feelings of calmness and happiness, often mixed with anxious passivity experiences. Fur thermore, drug sessions influenced some of the sub jects' perspective on matters of everyday life for at least a week after drug intake in a way that may be consid ered "therapeutic" in some cases. The summary results of this psychometric study, in part, confIrmed what was known about the effects of MOE from anecdotal reports. However, a more precise picture emerges from our data. The entactogens induce pronounced mental ef fects which do not closely resemble those of hallucino genic agents. Hence, it may be concluded that they rep resent a new class of psychoactive substances. Despite reports that entactogens are generally safe, and even despite the conceivable beneflcial effects, our data sug gest that the safety of these agents may depend upon the setting in which the substances are used.
Generally speaking, the study of psychoactive substances under controlled laboratory conditions represents a research strategy that merits further inquiry for several reasons. As a methodologic tool, experimen tal psychosis can be studied with a broad array of psy chologic as well as biologic techniques. From a system atic perspective, the study of the effects of psychoactive substances enhances our general understanding of psy chiatric phenomena, from subtle subjective psycho pat hological experiences to the underlying biologic brain mechanisms, and even allows correlational anal yses, bridging the "gap" between the mental and the physical. Lastly, from the point of view of public health, it is of utmost importance to society to have access to valid knowledge about the effects of substances that are widely used by the general public.
